Please try another search
GenNBio Inc. operates in the bio industry in South Korea. It engages in the research and development of xenogeneic organs; conducts non-clinical trial service on primates and rodents; development of artificial organs and new drugs; and is involved in pharmaceutical and medical device distribution business; as well as operates a transplant hospital. The company also offers xenotransplantation process, which is transplanting cells, organs, tissues, etc. from animals to humans. The company was formerly known as KD Nature & Bio CO.,LTD and changed its name to GenNBio Inc. in December 2018. GenNBio Inc. was founded in 1999 and is headquartered in Pyeongtaek-si, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Hae-Gil Lee | 58 | - | Director |
Hwa-Gun Lee | 65 | - | Director |
Joon-Young Kim | 58 | - | External Director |
Je-Soo Lee | 62 | - | Director |
Hui-Jin Kim | 55 | - | Head of Manufacturing Division and Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review